Comparative Pharmacology
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus DYMISTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus DYMISTA.
CLEMASTINE FUMARATE vs DYMISTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
Azelastine is a histamine H1-receptor antagonist; fluticasone propionate is a corticosteroid with anti-inflammatory activity. The combination reduces nasal symptoms by blocking histamine receptors and inhibiting inflammatory mediators.
1.34 mg orally twice daily; max 8.04 mg/day
One spray (137 mcg azelastine hydrochloride/50 mcg fluticasone propionate) per nostril twice daily, intranasal.
None Documented
None Documented
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
Azelastine: terminal half-life ~22 hours (plasma) with long-lasting antihistamine effect. Fluticasone propionate: terminal half-life ~7.8 hours (intravenous), but intranasal systemic exposure is very low.
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Azelastine: ~75% renal (primarily as parent and metabolites), ~25% fecal. Fluticasone propionate: <5% renal, >95% fecal as parent and metabolites.
Category C
Category C
Antihistamine
Antihistamine/Corticosteroid Combination